Metronidazole Immediate Release Formulations: A Fasting Randomized Open-Label Crossover Bioequivalence Study in Healthy Volunteers

Abstract

Metronidazole is a BCS (Biopharmaceutics Classification System) class 1 drug, traditionally considered the choice drug in the infections treatment caused by protozoa and anaerobic microorganisms. This study aimed to evaluate bioequivalence between 2 different marketed 250 mg metronidazole immediate release tablets. A randomized, open-label, 2×2 crossover study was performed in healthy Brazilian volunteers under fasting conditions with a 7-day washout period. The formulations were administered as single oral dose and blood was sampled over 48 h. Metronidazole plasma concentrations were determined by a liquid chromatography mass spectrometry (LC-MS/MS) method. The plasma concentration vs. time profile was generated for each volunteer and the pharmacokinetic parameters C_max, T_max, AUC_0–t, AUC_0–∞, k_e, and t_1/2 were calculated using a noncompartmental model. Bioequivalence between pharmaceutical formulations was determined by calculating 90% CIs (Confidence Intervall) for the ratios of C_max, AUC_0–t, and AUC_0–∞ values for test and reference using log-transformed data. 22 healthy volunteers (11 men, 11 women; mean (SD) age, 28 (6.5) years [range, 21–45 years]; mean (SD) weight, 66 (9.3) kg [range, 51–81 kg]; mean (SD) height, 169 (6.5) cm [range, 156–186 cm]) were enrolled in and completed the study. The 90% CIs for C_max (0.92–1.06), AUC_0–t (0.97–1.02), and AUC_0–∞ (0.97–1.03) values for the test and reference products fitted in the interval of 0.80–1.25 proposed by most regulatory agencies, including the Brazilian agency ANVISA. No clinically significant adverse effects were reported. After pharmacokinetics analysis, it concluded that test 250 mg metronidazole formulation is bioequivalent to the reference product according to the Brazilian agency requirements.

Key words

metronidazole - human plasma - bioequivalence - biowaiver - HPLC-MS/MS

• References

• 1 Korolkovas A. Dicionário Terapêutico Guanabara 2008/2009. Rio de Janeiro; Brazil: 2008
• 2 Drug Information Handbook International Lexi-Comp Inc 2005
• 3 Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333-1343
• 4 Klotz U. Pharmacokinetic Considerations in the Eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38 (03) 243-270
• 5 Jain P, Jain S, Prasad KN et al. Polyelectrolyte coated multilayered liposomes (Nano capsules) for the treatment of Helicobacter pylori infection. Mol Pharmaceutics 2009; 6 (02) 593-603
• 6 Ueki N, Miayke K, Kusunoki M et al. Impact of quadrupole regimen of clarithromycin added to metronidazole-containig triple theraphy against Helicobacter pylori infection following clarithromycin-containig triple theraphy failure. Helicobacter 2009; 14: 91-99
• 7 Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman: As bases farmacológicas da terapêutica. 10 ed. Rio de Janeiro; RJ: 2001: 1506
• 8 Lamp KC, Freeman CD, Klutman NE et al. Pharmacokinetics and pharmacodynamics of nitromidazole antimicrobials. Clin Phar 1999; 36 (05) 353-373
• 9 Amidon GL, Lennernãs H, Shah VP et al. A theoretical basis for a Biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pram Res 1995; 12 (03) 413-420
• 10 World Health Organization . Expert Committee on Specification for Pharmaceutical Preparation. 40 Report. Geneva: WHO; 2006: 478
• 11 US Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products – general considerations, 2002. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdf Accessed June 1, 2010
• 12 Alves AJ, Auino TM, Neto JLC et al. Bioequivalence between two metronidazole formulations. Latin American J Pharm 2007; 26 (02) 266-269
• 13 Gatchev E, Bräter M, De Mey C. Bioequivalence of a novel oral metronidazole formulation. Arzneimittelforschung 2006; 56 (08) 612-616
• 14 Muscara MN, De Nucci G. Bioavailability of four pharmaceutical formulations of metronidazole tested on normal healthy volunteers. Brazilian J Med Bio Research 1991; 24 (12) 1251-1260
• 15 Emami J, Ghassami N, Hamed H. A rapid and sensitive HPLC method for the analysis of metronidazole in human plasma: application to single dose pharmacokinetic and bioequivalence studies. DARU 2006; 14 (01) 15-21
• 16 Ogata H, Aoyagi N, Kaniwa N et al. Bioavailability of metronidazole from sugar-coated tablets in humans I. Effect of gastric acidity and correlation with in vitro dissolution rate. Int J Pharm 1985; 23 (03) 277-288
• 17 Shargel L, Yu AB. Applied Biopharmaceutics and Pharmacokinetics. 4rd ed. Norwalk, Conn: Appleton & Lange; 1999
• 18 Dos Reis Serra CH, Mori Koono EE, Kano EK et al. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: An open-label, randomized, single-dose, two-way crossover study. Clin Ther 2008; 30: 902-908
• 19 Abdou HM. Dissolution, Bioavailability and Bioequivalence. Easton, PA: Mack Pub Co; 1989: 554
• 20 Chen ML, Shah V, Patnaik R. Bioavailability and bioequivalence: An FDA regulatory overview. Pharm Res 2001; 18: 1645-1650
• 21 Silva MF, Schramm SG, Kano EK et al. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clin Ther 2010; 32 (04) 565-758
• 22 Storpirtis S, Gonçalves JE, Chiann C et al. Biofarmacotécnica. 1 ed. Rio de Janeiro; RJ: 2009: 321
• 23 Brazil. Laws, decrees, etc. Normative instruction IN no. 4, from August 3, 2011. Official Diary from Union, Brasília, August 5, 201. Section 1. [The National Health Surveillance Agency (ANVISA) approves drugs list to be consider as biowaiver from bioavailability and bioequivalence assays based on Biopharmaceutical Classification System (BCS)]. 2011. http://e-legis.anvisa.gov.br/leisref/public/showAct.php?id=21746&word= Accessed on July 1, 2012
• 24 World Medical Association. Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. http://www.wma.net/en/60about/70history/01declarationHelsinki/index.html Accessed June 1, 2010
• 25 European Agency for the Evaluation of Medicinal Products (EMA), International Conference on Harmonisation, World Health Organization (WHO). Guideline for Good Clinical Practice. ICH Topic E6 (R1) http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf Accessed June 1, 2010
• 26 Brazil. Laws, decrees, etc. Resolution RE no. 898, from March 29, 2003. Official Diary from Union, Brasília, June 2, 2003. Section 1. [The National Health Surveillance Agency (ANVISA) approves a bioavailability and bioequivalence assays for planning and statistic step guide]. 2003 http://e-legis.anvisa.gov.br/leisref/public/showAct.php?id=21746&word= Accessed on July 1, 2012
• 27 Hoffman C, Focke N, Franke G et al. Comparative Bioavailability of metronidazole formulations (Vagimid) after oral and vaginal administration. Int J clin Pharm Ther 1995; 33 (04) 232-239
• 28 Brazil. Laws, decrees, etc. Resolution RE no. 1170, from April 19, 2006. Official Diary from Union, Brasília, April 24, 2006. Section 1. [The National Health Surveillance Agency (ANVISA) approves a bioavailability and bioequivalence assays for drugs guide]. 2006 http://e-legis.anvisa.gov.br/leisref/public/showAct.php?id=21746&word= Accessed on June 1, 2010
• 29 Spandrel KA, Schieriver CA, Pendland SL et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacyn at 750 mg and various doses of metronidazole in healthy adult subjects. Antimicrob Agents Chemother 2004; 48 (12) 4597-4605
• 30 European Agency for the Evaluation of Medicinal Products (EMA), International Conference on Harmonisation, World Health Organization (WHO). Guideline on the investigation of Bioequivalence (R1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf Accessed May 14, 2011
• 31 Silva M, Schramm S, Kano E et al. Development and validation of a HPLC-MS-MS method for quantification of metronidazole in human plasma. J Chromatographic Sci 2009; 47: 781-784
• 32 Brazil. Laws, decrees, etc. Resolution RE no. 899, from May 29, 2003. Official Diary from Union, Brasília, June 2, 2003. Section 1. [The National Health Surveillance Agency (ANVISA) approves a validation guide for analytic and bioanalytic methods]. 2003. http://e-legis.anvisa.gov.br/leisref/public/showAct.php?id=15132&word= Accessed June 1, 2010
• 33 Mitchel WA. Handbook of Basic Pharmacokinetics – Including Clinical Applications. Hamilton, Ill: Drug Intelligence Publications; 2004
• 34 United States Pharmacopeia 30 ed. Rockville: United States Pharmacopeial Convetion; 2007
• 35 National Health Surveillance Agency (ANVISA). Good Practice manual of bioavailability and bioequivalence, 2003. http://www.anvisa.gov.br/medicamentos/bioequivalencia/publicacoes/index.asp Accessed July 3, 2010
• 36 Brazil. Laws, decrees, etc. Resolution RE no. 898, from May 29, 2003. Official Diary from Union, Brasília, June 2, 2003. Section 1. [The National Health Surveillance Agency (ANVISA) approves a guide to planning and implementing the statistical phase of drugs bioavailability and bioequivalence]. 2003 http://e-legis.anvisa.gov.br/leisref/public/showAct.php?id=2489&word= Accessed June 1, 2010
• 37 Jackson AJ. (ed.) Generics and bioequivalence. Boca Raton: CRC Press; 1999: 49-100